Opinion|Videos|December 13, 2024
CAR-T Therapy in Standard-Risk Multiple Myeloma: Rationale and Patient Preparation
Panelists discuss the rationale for considering chimeric antigen receptor (CAR) T-cell therapy in standard-risk multiple myeloma and how health care providers help patients understand and prepare for the decision to pursue CAR T-cell treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Dr Castaneda: Ask Jammie:
- What is the rationale for considering chimeric antigen receptor (CAR) T-cell therapy as a treatment in standard-risk multiple myeloma?
Dr Castaneda: Ask Jammie:
- How do you help patients understand the option of CAR T cell as a therapy, and what is your role in preparing them for this decision?
Advertisement
Related to this article
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.
VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.
Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.
Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.
Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Building out a Radiopharmaceuticals Program in Oncology Care
3
Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma
4
How Emory Became the First Adopter of the Liberty Endovascular Robotic System
5